Semaglutide

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist sharing 94% sequence homology with endogenous human GLP-1. Three structural modifications confer its extended duration of action: alanine at position 8 is replaced with aminoisobutyric acid (Aib) to resist DPP-4 proteolysis; a C18 fatty diacid chain is attached via a linker at Lys26, enabling reversible albumin binding that reduces renal clearance and metabolic degradation; and Lys34 is replaced with arginine to prevent aberrant fatty acid attachment. These changes yield a plasma half-life of approximately seven days, supporting once-weekly subcutaneous dosing.

At pancreatic beta cells, GLP-1 receptor activation couples to Gs protein, elevating cyclic AMP and stimulating insulin secretion in a strictly glucose-dependent manner. This mechanism markedly limits hypoglycemia risk in monotherapy. Glucagon release from alpha cells is concurrently suppressed through the same glucose-dependent mechanism. Gastric emptying is delayed in the early postprandial phase, attenuating postprandial glucose excursions.

GLP-1 receptors distributed across the hypothalamus, brainstem, and cortex mediate central appetite suppression. Semaglutide activates hypothalamic AMPK signaling pathways, reinforces leptin-driven anorexigenic circuits, and suppresses orexigenic signals, reducing caloric intake. Additional downstream effects include promotion of brown adipose tissue thermogenesis and inhibition of adipogenesis through suppression of Wnt/beta-catenin signaling.

Semaglutide has been evaluated in two landmark clinical trial programs encompassing type 2 diabetes and chronic weight management, generating among the largest bodies of phase 3 data for any GLP-1 receptor agonist.

The SUSTAIN program assessed once-weekly subcutaneous semaglutide (0.5 mg and 1.0 mg) in type 2 diabetes across ten trials. SUSTAIN 1-5 (combined n=3,918) demonstrated HbA1c reductions of 1.1% to 2.2% from mean baselines of 8.1-8.4%, with weight reductions of approximately 3.6 to 6.9 kg versus comparators. Between 45% and 66% of participants on semaglutide 1.0 mg achieved at least 5% weight loss versus 4-30% on comparators. SUSTAIN 6 (n=3,297), a cardiovascular outcomes trial over two years, showed a hazard ratio of 0.74 for the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke versus placebo, establishing cardiovascular risk reduction in patients with established disease. SUSTAIN 6 also detected a 76% higher rate of diabetic retinopathy complications in semaglutide-treated patients with pre-existing retinopathy, attributed by investigators to the rapidity of glycemic correction rather than direct drug toxicity.

The STEP program evaluated subcutaneous semaglutide 2.4 mg weekly for chronic weight management in individuals without diabetes. STEP 1 (n=1,961; Wilding et al., NEJM 2021) found a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo; 86.4% of participants achieved at least 5% weight loss versus 31.5% on placebo. STEP 8 confirmed superiority over liraglutide 3.0 mg for weight reduction.

The PIONEER program studied oral semaglutide. PIONEER 6 (n=3,183) demonstrated noninferiority for MACE with a hazard ratio of 0.79. The SOUL trial (n=9,650) subsequently confirmed that oral semaglutide reduced MACE by 14% overall, with consistent benefit independent of concomitant SGLT2 inhibitor use. The FLOW trial demonstrated a 24% reduction in a composite renal endpoint in patients with type 2 diabetes and chronic kidney disease treated with semaglutide versus placebo.

Typical dosage: 0.25-2.4 mg (weekly).

Three FDA-approved formulations exist, each requiring dose escalation to minimize gastrointestinal adverse effects. All doses are per FDA prescribing information.

Ozempic (subcutaneous injection; indicated for type 2 diabetes and cardiovascular risk reduction): • Initiate at 0.25 mg subcutaneously once weekly for 4 weeks (not a therapeutic dose; intended for tolerability) • Escalate to 0.5 mg once weekly for at least 4 weeks • Standard maintenance: 1.0 mg once weekly • May increase to 2.0 mg once weekly for additional glycemic control • Administer in abdomen, thigh, or upper arm; rotate injection sites

Wegovy (subcutaneous injection; indicated for chronic weight management in adults and adolescents aged 12 and older meeting BMI criteria): • Weeks 1-4: 0.25 mg once weekly • Weeks 5-8: 0.5 mg once weekly • Weeks 9-12: 1.0 mg once weekly • Weeks 13-16: 1.7 mg once weekly • Week 17 onward: 2.4 mg once weekly (maintenance dose)

Rybelsus (oral tablet; indicated for type 2 diabetes): • 3 mg once daily for 30 days • Increase to 7 mg once daily • May increase to 14 mg once daily for additional control • Must be taken fasting with no more than 120 mL water; delay food, beverages, and other medications at least 30 minutes

No dose adjustment is required for renal or hepatic impairment per FDA labeling.

This information is provided for educational reference only and does not constitute medical advice. All dosing decisions must be individualized by a licensed healthcare provider based on clinical circumstances, comorbidities, and concomitant medications.

Lyophilized (before reconstitution)

Refrigerate 2–8°C before first use. Do not freeze. Protect from light in the original carton. Rybelsus (oral tablet) is stored at 20–25°C in a dry place in the original blister until administration.

Reconstituted

Ozempic: after first use, the pen may be kept at room temperature (≤30°C) or refrigerated (2–8°C) for up to 56 days. Wegovy: after first use, keep the pen refrigerated (2–8°C) or at room temperature (≤30°C) for up to 28 days with the cap on. Rybelsus: not applicable (oral tablet).

For general storage chemistry (bacteriostatic vs sterile water, freeze-thaw, BUD framework), see Storage & handling.

Last reviewed: July 1, 2026

Semaglutide is frequently used alongside other antidiabetic and cardiometabolic agents, and several combinations carry clinical trial data.

Metformin is the most common co-medication in clinical practice. Approximately 77% of participants across the SUSTAIN trials were receiving metformin at baseline. The combination is considered a standard treatment approach for type 2 diabetes in major clinical guidelines, with additive glycemic benefit and no significant pharmacokinetic interaction.

SGLT2 inhibitors are supported by prospective trial data. Prespecified analyses from the SOUL trial (n=9,650) showed that semaglutide's 14% MACE reduction was maintained regardless of whether participants were concurrently using an SGLT2 inhibitor, and no significant additional safety signals emerged. The FLOW trial similarly demonstrated consistent renal protective effects with or without concomitant SGLT2 inhibitor use. Because GLP-1 receptor agonists and SGLT2 inhibitors operate through distinct mechanisms (vascular and metabolic versus renal hemodynamic and cardiac energetic), additive benefit is mechanistically plausible, though trials specifically powered to test additive cardiovascular or renal outcomes are limited.

Insulin and sulfonylurea combinations are used clinically but require dose reductions to mitigate hypoglycemia risk.

Cagrilintide (an amylin analogue) combined with semaglutide (the CagriSema regimen) has been evaluated in a phase 3 clinical trial (NEJM, 2025), showing greater weight loss than either agent alone. This combination remains investigational and is not FDA-approved as of 2026.

Semaglutide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Nausea, vomiting, diarrhea, constipation, potential pancreatitis risk

Gastrointestinal adverse effects are the most common and are dose-dependent. Nausea affects approximately 20% of patients in type 2 diabetes trials at standard doses and up to 44% in weight management trials at the 2.4 mg dose. Vomiting, diarrhea, constipation, abdominal pain, and decreased appetite are also frequently reported. Most gastrointestinal events are mild to moderate in severity, occur predominantly during dose escalation, and typically resolve within approximately two weeks. The structured dose-escalation schedule is designed to improve tolerability.

Semaglutide carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodents at clinically relevant exposures. Whether this risk applies to humans is not established. Semaglutide is therefore contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Hypoglycemia risk is low with monotherapy due to the glucose-dependent mechanism. When combined with insulin or sulfonylureas, dose reductions of those agents are recommended.

Diabetic retinopathy complications were observed at a 76% higher rate in SUSTAIN 6 among semaglutide-treated patients with pre-existing retinopathy, attributed to the rapidity of HbA1c lowering. Ophthalmic monitoring is warranted in patients with baseline retinopathy.

Additional documented adverse effects include acute pancreatitis (reported in trials; causality uncertain; prior pancreatitis warrants caution), gallbladder disease (cholelithiasis, cholecystitis), and acute kidney injury from volume depletion secondary to gastrointestinal losses.

Semaglutide is contraindicated in pregnancy; discontinuation at least two months before planned conception is recommended. Use during breastfeeding is not advised due to insufficient safety data.

Drug interaction: levothyroxine exposure is increased by approximately 33% with concomitant semaglutide use; thyroid function monitoring is advisable in patients on thyroid hormone replacement. No dose adjustment is required for renal or hepatic impairment.